Effect of dipyridamole during acute stroke: Exploring antithrombosis and neuroprotective benefits

Annals of the New York Academy of Sciences

Volumn 1207, Issue , 2010, Pages 71-75

  d'Esterre, C D ^a,b,c   Lee, T Y ^a,b,c  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b LAWSON HEALTH RESEARCH INSTITUTE   (Canada)

^c ROBARTS RESEARCH INSTITUTE   (Canada)

Author keywords

Antiplatelet drug; Dipyridamole; Inflammation; Neuroprotection; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE; ADENYLATE CYCLASE; CYCLIC AMP; CYCLIC GMP PHOSPHODIESTERASE; DIPYRIDAMOLE; GELATINASE B; INTERCELLULAR ADHESION MOLECULE 1; NITRIC OXIDE; PLASMINOGEN ACTIVATOR; REACTIVE OXYGEN METABOLITE; TISSUE PLASMINOGEN ACTIVATOR; TUMOR NECROSIS FACTOR ALPHA; UROKINASE; ANTITHROMBOCYTIC AGENT; FIBRINOLYTIC AGENT; NEUROPROTECTIVE AGENT;

ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BRAIN ISCHEMIA; BRAIN PERFUSION; EMBOLISM; ENDOTHELIUM CELL; ENZYME INHIBITION; FIBRINOLYSIS; HUMAN; INFLAMMATION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PLEIOTROPY; PROTEIN EXPRESSION; RECURRENT DISEASE; STROKE; THROMBOCYTE; THROMBOCYTE ACTIVATION; VASCULAR ENDOTHELIUM; ANIMAL; BRAIN CIRCULATION; CEREBRAL ARTERY DISEASE; DISEASE MODEL; DRUG EFFECT; PATHOPHYSIOLOGY; RABBIT; REVIEW;

ANIMALS; CEREBROVASCULAR CIRCULATION; DIPYRIDAMOLE; DISEASE MODELS, ANIMAL; FIBRINOLYTIC AGENTS; HUMANS; INFARCTION, MIDDLE CEREBRAL ARTERY; NEUROPROTECTIVE AGENTS; PLATELET AGGREGATION INHIBITORS; RABBITS; RECURRENCE; STROKE;

EID: 78149241207     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2010.05801.x     Document Type: Article

References (34)

1. De Schryver E.L., A. Algra & J. van Gijn. 2008. Dipyridamole for preventing stroke and other vascular events in patients with vascular disease. An update. Stroke 38: 1397-1398.
2. Diener, H.C., L. Cunha, C. Forbes, et al. 1996. European stroke prevention study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J. Neurol. Sci. 143: 1-13.
3. Greisenegger, S., S. Tentschert, M. Weber, et al. 2006. Prior therapy with antiplatelet agents is not associated with outcome in patients with acute ischemic stroke/tia. J. Neurol. 253: 648-652.
4. Ovbiagele, B., B.H. Buck, D.S. Liebeskind, et al. 2008. Prior antiplatelet use and infarct volume in ischemic stroke. J. Neurol. Sci. 264: 140-144.
5. Sivenius, J., L. Cunha, H.C. Diener, et al. 1999. Antiplatelet treatment does not reduce the severity of subsequent stroke. European stroke prevention study 2 working group. Neurology 53: 825-829.
6. Bath, P.M. 2007. Is there a link between aspirin therapy and stroke severity? Nat. Clin. Pract. Neurol. 3: 12-13.
7. Rodriguez-Yanez, M. & J. Castillo. 2008. Role of inflammatory markers in brain ischemia. Curr. Opin. Neurol. 21: 353-357.
8. Batista, L.M., D. Crandell, F.O. Lima & D.M. Greer. 2010. Pharmacokinetics of extended-release dipyridamole following administration through a gastrostomy tube: an openlabel, case-control, two-centre study. Clin. Drug Investig. 30: 483-488.
9. Kim, H.H.,N. Sawada, G. Soydan, et al. 2008.Additive effects of statin and dipyridamole on cerebral blood flowand stroke protection. J. Cereb. Blood Flow Metab. 28: 1285-1293.
10. Stafford, A. 1966. Potentiation of adenosine and the adenine nucleotides by dipyridamole. Br. J. Pharmacol. Chemother. 28: 218-227.
11. Sudlow, C. 2005. What is the role of dipyridamole in longterm secondary prevention after an ischemic stroke or transient ischemic attack? CMAJ 173: 1024-1026.
12. Ohisalo, J.J. 1987. Regulatory functions of adenosine. Med. Biol. 65: 181-191.
13. Chakrabarti, S. & J.E. Freedman. 2008. Dipyridamole, cerebrovascular disease, and the vasculature. Vascul. Pharmacol. 48: 143-149.
14. Heistad,D.D.,M.L.Marcus, J.K. Gourley,D.W. Busija. 1981. Effect of adenosine and dipyridamole on cerebral blood flow. Am. J. Physiol. 240: H775-H780.
15. Dresse, A., C. Chevolet, D. Delapierre, et al. 1982. Pharmacokinetics of oral dipyridamole (persantine) and its effect on platelet adenosine uptake in man. Eur. J. Clin. Pharmacol. 23: 229-234.
16. Hasday, J.D. & R.G. Sitrin. 1987. Dipyridamole stimulates urokinase production and suppresses procoagulant activity of rabbit alveolar macrophages: a possible mechanism of antithrombotic action. Blood 69: 660-667.
17. Kim, J.A., N.D. Tran, W. Zhou, M. Fisher. 2005. Dipyridamole enhances tissue plasminogen activator release by brain capillary endothelial cells. Thromb. Res. 115: 435- 438.
18. Chan, P.H. 2001. Reactive oxygen radicals in signaling and damage in the ischemic brain. J. Cereb. Blood Flow Metab. 21: 2-14.
19. Chakrabarti, S., O. Vitseva, D. Iyu, et al. 2005. The effect of dipyridamole on vascular cell-derived reactive oxygen species. J. Pharmacol. Exp. Ther. 315: 494-500.
20. Iuliano, L., J.Z. Pedersen, G. Rotilio, et al. 1995. A potent chain-breaking antioxidant activity of the cardiovascular drug dipyridamole. Free Radic. Biol. Med. 18: 239-247.
21. Kusmic, C., C. Petersen, E. Picano, et al. 2000. Antioxidant effect of oral dipyridamole during cerebral hypoperfusion with human carotid endarterectomy. J. Cardiovasc. Pharmacol. 36: 141-145.
22. Selley,M.L., A.L. Czeti, J.A.McGuiness & N.G. Ardlie. 1994. Dipyridamole inhibits the oxidative modification of low density lipoprotein. Atherosclerosis 111: 91-97.
23. Simon, H.U., A. Haj-Yehia & F. Levi-Schaffer. 2000. Role of reactive oxygen species (ros) in apoptosis induction. Apoptosis 5: 415-418.
24. Huang, J., U.M. Upadhyay & R.J. Tamargo. 2006. Inflammation in stroke and focal cerebral ischemia. Surg. Neurol. 66: 232-245.
25. Libby, P., P.M. Ridker & G.K. Hansson. 2009. Inflammation in atherosclerosis: from pathophysiology to practice. J. Am. Coll. Cardiol. 54: 2129-2138.
26. Yudkin, J.S., M. Kumari, S.E. Humphries & V. Mohamed-Ali. 2000. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link. Atherosclerosis 148: 209- 214.
27. Croce, K. & P. Libby. 2007. Intertwining of thrombosis and inflammation in atherosclerosis. Curr. Opin. Hematol. 14: 55-61.
28. Emsley,H.C.&P.J.Tyrrell. 2002. Inflammationand infection in clinical stroke. J. Cereb. Blood Flow Metab. 22: 1399-1419.
29. Hallenbeck J.M. 2002. Inflammatory reactions at the bloodendothelial interface in acute stroke. Adv. Neurol. 1996;71: 281-297; discussion 297-300.
30. Al-Bahrani, A., S. Taha, H. Shaath & M. Bakhiet. 2007. Tnfalpha and il-8 in acute stroke and the modulation of these cytokines by antiplatelet agents. Curr. Neurovasc. Res. 4: 31-37.
31. Stanimirovic,D., A. Shapiro, J.Wong, et al. 1997. The induction of icam-1 in human cerebromicrovascular endothelial cells (hcec) by ischemia-like conditions promotes enhanced neutrophil/hcec adhesion. J. Neuroimmunol. 76: 193-205.
32. Wollner, A., S. Wollner & J.B. Smith. 1993. Acting via a2 receptors, adenosine inhibits the upregulation of MAC-1 (cd11b/cd18) expression on FMLP-stimulated neutrophils. Am. J. Respir. CellMol. Biol. 9: 179-185.
33. Marshall, J.C., Z. Malam & S. Jia. 2007. Modulating neutrophil apoptosis. Novartis Found. Symp. 280: 53-66. discussion 67-72, 160-164.
34. Feuerstein, G.Z., T. Liu & F.C. Barone. 1994. Cytokines, inflammation, and brain injury: role of tumor necrosis factoralpha. Cerebrovasc. Brain Metab. Rev. 6: 341-360